Zhitong Financial APP learned that Bishengyuan (00926) rose more than 6%. As of press time, it rose 6.41% to HK $4.65, with a turnover of HK $1.29 million. The company's shares have been strong recently, up 50% since September.
It is reported that the GLP-1 weight loss drugs represented by Smeagrup continue to be popular. Recently, overseas investment banks raised their sales forecasts for weight-loss drugs. Affected by this, the share prices of Novo-Nordisk A/S and Eli Lilly and Co, the two major weight-loss drug leaders in the United States, reached an all-time high, transmitted to the Hong Kong and A-share markets.
Among them, JPMorgan Chase & Co raised his forecast for the sales of weight-loss drugs, predicting that the annual sales of this GLP-1 agonist drug will exceed 100 billion US dollars by 2030.
It is worth mentioning that orlistat, the only weight-loss drug approved in China, as one of the core products of Bishengyuan, contributed 268 million yuan in revenue to the company in 2022, accounting for 28.4% of the total revenue.